Showing results (161-170 of 205) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy responseYann Godet, Elizabeth Fabre, Magalie Dosset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerDavid W Miles, Arlene Chan, Luc Y Dirix, et al.
European Journal of Cancer (Oxford, England : 1990)|May 23, 2016
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-upChristian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, et al.
Clinical Medicine Insights. Oncology|August 26, 2016
Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by ChemoradiotherapyClotilde Verlut, Guillaume Mouillet, Eloi Magnin, et al.
Breast Cancer Research and Treatment|March 27, 2010
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerCarlos H Barrios, Mei-Ching Liu, Soo Chin Lee, et al.
BMC Cancer|February 1, 2023
Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant settingXavier Pivot, Alexey Georgievitch Manikhas, Volodymyr Shamrai, et al.
BMJ Oncology|June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Frontiers in Oncology|September 9, 2020
Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study ProtocolJoris Mallard, Elyse Hucteau, Roland Schott, et al.
Scientific Reports|March 8, 2022
Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by ImmunohistochemistryZohair Selmani, Chloé Molimard, Alexis Overs, et al.
Plos One|September 23, 2021
A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumabMartin Demarchi, Pierre Coliat, Philippe Barthelemy, et al.
Pageof 21